Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Lorigerlimab · MGD-019, AEX-1344

Bispecific antibody · Immune activation, directed at Programmed cell death protein 1 (PDCD1) and Cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) · developed by MacroGenics

Phase 2 Most advanced trial
MGNX Developer
1 Registered trials

What is Lorigerlimab?

Lorigerlimab is a tetravalent, hinge-stabilized IgG4 bispecific antibody-like protein that binds both PD-1 and CTLA-4 on tumor-infiltrating lymphocytes. By blocking these two negative checkpoint receptors, it aims to enhance T-cell activation and proliferation. It is being studied in platinum-resistant ovarian, fallopian tube and peritoneal cancers, clear cell adenocarcinomas of gynecologic sites, and endometrial cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
MGD-019, AEX-1344
Drug type
Bispecific antibody
Targets
Programmed cell death protein 1 (PDCD1), Cytotoxic T-lymphocyte-associated antigen 4 (CTLA4)
Mechanism
Immune activation, directed at Programmed cell death protein 1 (PDCD1) and Cytotoxic T-lymphocyte-associated antigen 4 (CTLA4)
Pathways
T-cell activation, T-cell proliferation
Therapy area
Oncology
Developer
MacroGenics (MGNX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
JM802R57SA

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06730347 Phase 2 Platinum-resistant Ovarian Cancer Recruiting MGNX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Clear Cell Adenocarcinoma of CervixClear Cell Adenocarcinoma of Fallopian TubeClear Cell Adenocarcinoma of OvaryClear Cell Adenocarcinoma of PeritoneumClear Cell Adenocarcinoma of UterusClear Cell Adenocarcinoma of VaginaClear Cell Adenocarcinoma of VulvaEndometrial CancerPlatinum-Resistant Fallopian Tube CarcinomaPlatinum-resistant Ovarian CancerPlatinum-Resistant Primary Peritoneal Carcinoma

Other drugs acting on PDCD1 / CTLA4

More from MacroGenics

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the MGNX page.

Follow MGNX, the company behind Lorigerlimab

See MGNX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

MGNX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.